



Afluria[®] Quadrivalent (influenza vaccine) – Expanded indication

- On August 31, 2017, the [FDA approved](#) Seqirus' [Afluria Quadrivalent \(influenza vaccine\)](#) for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine in persons 5 years of age and older.
 - Previously, Afluria Quadrivalent was approved for persons 18 years of age and older.
- The efficacy of the expanded indication for Afluria Quadrivalent was demonstrated in a study of 2,278 children ages 5 – 17 years. Patients received one or two doses of Afluria Quadrivalent or a U.S.-licensed comparator quadrivalent influenza vaccine. The primary objective was to demonstrate that vaccination with Afluria Quadrivalent elicits an immune response that is not inferior to that of a comparator vaccine.
 - Immune responses to Afluria Quadrivalent were non-inferior to the comparator vaccine for all influenza strains.
- The recommended dosage of Afluria Quadrivalent is 1 or 2 doses at least one month apart for ages 5 – 8 years and 1 dose for ages 9 years and older by intramuscular injection.
 - Administration by needle and syringe is for 5 years of age and older.
 - Administration by the PharmaJet[®] Stratis[®] Needle-Free Injection System is for ages 18 through 64 years.
 - The preferred site for intramuscular injection is the deltoid muscle of the upper arm.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.